2. Search Result
Search Result
Results for "

Cardiac myocytes

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

3

Peptides

4

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113447
    11-Dehydrocorticosterone
    2 Publications Verification

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    11-Dehydrocorticosterone is a endogenous corticosteroid. 11-Dehydrocorticosterone can be a source of transcriptionally active glucocorticoid in cardiac myocytes and fibroblasts. 11-Dehydrocorticosterone can increase SGK mRNA expression in cardiac fibroblast .
    11-Dehydrocorticosterone
  • HY-B1906
    Streptomycin
    Maximum Cited Publications
    42 Publications Verification

    Agrept; Agrimycin; Streptomycin A

    		 Antibiotic Bacterial Infection Neurological Disease
    Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
    Streptomycin
  • HY-111536
    Mitochonic acid 5
    4 Publications Verification

    MA-5

    		 Oxidative Phosphorylation Mitochondrial Metabolism Cardiovascular Disease
    Mitochonic acid 5 binds mitochondria and ameliorates renal tubular and cardiac myocyte damage. Mitochonic acid 5 modulates mitochondrial ATP synthesis.
    Mitochonic acid 5
  • HY-12593
    GS967
    5+ Cited Publications

    		 Sodium Channel Cardiovascular Disease
    GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late INa ) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.
    GS967
  • HY-108591
    L-364,373

    R-L3

    		 Potassium Channel Cardiovascular Disease
    L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .
    L-364,373
  • HY-B1906R
    Streptomycin (Standard)

    Agrept (Standard); Agrimycin (Standard); Streptomycin A (Standard)

    		 Reference Standards Antibiotic Bacterial Infection Neurological Disease
    Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
    Streptomycin (Standard)
  • HY-12773A
    5-Hydroxy Propafenone hydrochloride

    GPV-129 hydrochloride

    		 Others Biochemical Assay Reagents Potassium Channel Cardiovascular Disease
    5-Hydroxy Propafenone (hydrochloride) is an inhibitor of cardiac myocyte repolarizing currents. 5-Hydroxy Propafenone is an active metabolite of propafenone. 5-Hydroxy Propafenone (hydrochloride) inhibits transient outward potassium current (Ito) in isolated human arterial myocytes with an IC50 of 1.5 μM. 5-Hydroxy Propafenone (hydrochloride) is potent Ito inhibitor in neonatal rat ventricular myocytes .
    5-Hydroxy Propafenone hydrochloride
  • HY-116540A
    L 858051 dihydrochloride

    7DMB-Forskolin

    		 Adenylate Cyclase Cardiovascular Disease
    L 858051 dihydrochloride is an analog of Forskolin (HY-15371) that activates adenylate cyclase while also having modulatory effects on intracellular cAMP levels, particularly enhancing the CNG current in cardiac myocytes .
    L 858051 dihydrochloride
  • HY-116540
    L 858051

    7DMB-Forskolin free base

    		 Adenylate Cyclase Cardiovascular Disease
    L 858051 is an analog of Forskolin (HY-15371) that activates adenylate cyclase while also having modulatory effects on intracellular cAMP levels, particularly enhancing the CNG current in cardiac myocytes .
    L 858051
  • HY-P3054
    S6 peptide

    		Ribosomal S6 Kinase (RSK) Cardiovascular Disease
    S6 peptide is a potentially important lamin kinase. S6 peptide is involved in the process of cardiac hypertrophy induced by mechanical loading. S6 peptide can be activated by many kinds of growth factors .
    S6 peptide
  • HY-P1428A
    RFRP-1(human) TFA

    		Neuropeptide Y Receptor Cardiovascular Disease
    RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
    RFRP-1(human) TFA
  • HY-126763
    ATI22-107

    		Phosphodiesterase (PDE) Calcium Channel Others
    ATI22-107 is a dual-pharmacophore compound designed to simultaneously inhibit cardiac phosphodiesterase (PDE-III) and L-type calcium channels (LTCC), with activity that has specific effects on calcium cycling and contractility in cat ventricular myocytes and trabeculae.
    ATI22-107
  • HY-P5772
    Jingzhaotoxin-II

    		Sodium Channel Neurological Disease
    Jingzhaotoxin-II, a 32 amino acid residues including two acidic and two basic residues, is a neurotoxin. Jingzhaotoxin-II inhibits voltage-gated sodium channels (VGSC) that significantly slows rapid inactivation of TTX-resistant (TTX-R) VGSC on cardiac myocytes with the IC50 of 0.26 μM .
    Jingzhaotoxin-II
  • HY-12724A
    Guanabenz hydrochloride

    		Parasite Adrenergic Receptor Cardiovascular Disease Cancer
    Guanabenz hydrochloride is an orally active α-2-adrenoceptor agonist. Guanabenz hydrochloride has antihypertensive effect and antiparasitic activity. Guanabenz hydrochloride interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz hydrochloride also is used for the research of high blood pressure .
    Guanabenz hydrochloride
  • HY-12724
    Guanabenz
    2 Publications Verification

    		 Adrenergic Receptor Parasite Cardiovascular Disease Cancer
    Guanabenz is an orally active α-2-adrenoceptor agonist. Guanabenz has antihypertensive effect and antiparasitic activity. Guanabenz interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz also is used for the research of high blood pressure .
    Guanabenz
  • HY-12593R
    GS967 (Standard)

    		Sodium Channel Cardiovascular Disease
    GS967 (Standard) is the analytical standard of GS967. This product is intended for research and analytical applications. GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late INa ) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.
    GS967 (Standard)
  • HY-174479
    Mouse Mef2c mRNA

    		mRNA Cardiovascular Disease
    Mouse Mef2c mRNA encodes the mouse myocyte enhancer factor 2C (Mef2c) protein, a transcription activator which binds specifically to the MEF2 element present in the regulatory regions of many muscle-specific genes. Mef2c controls cardiac morphogenesis and myogenesis, and is also involved in vascular development, neurogenesis and the development of cortical architecture.
    Mouse Mef2c mRNA
  • HY-107372D
    Uridine triphosphate tetrasodium

    UTP tetrasodium; Uridine 5'-triphosphate tetrasodium

    		 Biochemical Assay Reagents Cardiovascular Disease
    Uridine triphosphate (tetrasodium) (UTP (tetrasodium)) is released during cardiac ischemia. Uridine triphosphate (tetrasodium) belongs to a family of extracellular nucleotide signaling molecules. Uridine triphosphate (tetrasodium) can stimulate vasodilation, automaticity in ventricular myocytes and release tussue-quantitative activator (t-PA). Uridine triphosphate (tetrasodium)-induced t-PA release can dissolve the thrombus in myocardial infarction .
    Uridine triphosphate tetrasodium
  • HY-12724AR
    Guanabenz hydrochloride (Standard)

    		Parasite Adrenergic Receptor Cardiovascular Disease Cancer
    Guanabenz (hydrochloride) (Standard) is the analytical standard of Guanabenz (hydrochloride). This product is intended for research and analytical applications. Guanabenz hydrochloride is an orally active α-2-adrenoceptor agonist. Guanabenz hydrochloride has antihypertensive effect and antiparasitic activity. Guanabenz hydrochloride interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz hydrochloride also is used for the research of high blood pressure .
    Guanabenz hydrochloride (Standard)
  • HY-159108
    AZ683

    		c-Fms Cardiovascular Disease
    AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (Ki=8 nM; IC50=6 nM). AZ683 has good oral bioavailability. [ 11C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) .
    AZ683
  • HY-106761
    Oxodipine

    		Calcium Channel Cardiovascular Disease Others
    Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs .
    Oxodipine
  • HY-A0113
    Cilazaprilat

    Ro 31-3113

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.
    Cilazaprilat
  • HY-107813R
    Amikacin sulfate (Standard)

    BAY 41-6551 sulfate (Standard)

    		 Reference Standards Bacterial Antibiotic Infection Cancer
    Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
    Amikacin sulfate (Standard)
  • HY-119378
    AK 295

    CX 295

    		 Proteasome Apoptosis Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    AK 295 (CX 295) is a selective calpain inhibitor. AK 295 can inhibit apoptosis through a calpain-dependent pathway. AK 295 shows potent neuroprotective effect. AK 295 can inhibit the activity of the cysteine protease calpain and reduce myocardial injury. AK 295 can be used for the researches of infection, inflammation, cardiovascular and neurological disease, such as stroke and viral myocarditis .
    AK 295
  • HY-137683A
    Guanosine 5'-O-(2-thiodiphosphate) trisodium

    GDPβS trisodium

    		 Adenylate Cyclase Cardiovascular Disease
    Guanosine 5'-O-(2-thiodiphosphate) (trisodium) (GDPβS (trisodium)) is a non-hydrolyzable derivative of GDP. Guanosine 5'-O-(2-thiodiphosphate) (trisodium) is an inhibitor of adenylyl caclase (AC) (Ki = 600 nM). Guanosine 5'-O-(2-thiodiphosphate) (trisodium) partially activates AC in the absence of GPT in cerebral cortex membranes of rodent models (EC50 = 400 nM). Guanosine 5'-O-(2-thiodiphosphate) (trisodium) prevents the release of norepinephrine-induced nitric oxide in cardiac ventricular myocytes .
    Guanosine 5'-O-(2-thiodiphosphate) trisodium
  • HY-124702
    ICA-105574
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    ICA-105574 is a potent and efficacious hERG channel activator. The primary mechanism by which ICA-105574 potentiates hERG channel activity is by removing hERG channel inactivation. ICA-105574 steeply potentiates current amplitudes more than 10-fold with an EC50 value of 0.5 +/- 0.1 μM and a Hill slope (n(H)) of 3.3 +/- 0.2. ICA-105574 can prevent arrhythmias induced by cardiac delayed repolarization. ICA-105574 shortens action potential duration in ventricular myocytes concentration-dependently .
    ICA-105574
  • HY-121183
    Aprikalim

    RP 52891

    		 Potassium Channel Cardiovascular Disease
    Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions .
    Aprikalim
  • HY-N1508
    Ecliptasaponin A

    		MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .
    Ecliptasaponin A
  • HY-122620
    Rafutrombopag (tautomerism)

    Hetrombopag (tautomerism); SHR-8735 (tautomerism)

    		 Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK Cardiovascular Disease Inflammation/Immunology
    Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
    Rafutrombopag (tautomerism)
  • HY-145589
    Rafutrombopag

    Hetrombopag; SHR-8735

    		 Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK Cardiovascular Disease Inflammation/Immunology
    Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
    Rafutrombopag
  • HY-A0236
    Aprindine

    		Sodium Channel Potassium Channel Calcium Channel Calmodulin Cardiovascular Disease
    Aprindine is an Ib-class anti-arrhythmic agent. Aprindine mainly exerts its effect by blocking sodium channels (INa), thereby reducing the excitability and conduction velocity of cardiac muscle cells. Aprindine significantly inhibits delayed potassium currents, which helps to prolong the atrial effective refractory period (AERP) and inhibit the occurrence of atrial fibrillation. Aprindine can also regulate intracellular calcium ion concentration by inhibiting Na +/Ca 2+ exchange current (INCX), thereby further stabilizing cardiac electrical activity. Aprindine can be used for the study of atrial fibrillation (AF) and ventricular arrhythmias .
    Aprindine
  • HY-A0236A
    Aprindine hydrochloride

    		Sodium Channel Potassium Channel Calcium Channel Calmodulin Cardiovascular Disease
    Aprindine hydrochloride is an Ib-class anti-arrhythmic agent. Aprindine hydrochloride mainly exerts its effect by blocking sodium channels (INa), thereby reducing the excitability and conduction velocity of cardiac muscle cells. Aprindine hydrochloride significantly inhibits delayed potassium currents, which helps to prolong the atrial effective refractory period (AERP) and inhibit the occurrence of atrial fibrillation. Aprindine hydrochloride can also regulate intracellular calcium ion concentration by inhibiting Na +/Ca 2+ exchange current (INCX), thereby further stabilizing cardiac electrical activity. Aprindine hydrochloride can be used for the study of atrial fibrillation (AF) and ventricular arrhythmias .
    Aprindine hydrochloride
  • HY-16734A
    Amiselimod hydrochloride

    MT-1303 hydrochloride

    		 LPL Receptor Cardiovascular Disease Inflammation/Immunology
    Amiselimod (MT-1303) hydrochloride is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod hydrochloride is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod hydrochloride inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod hydrochloride inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimod hydrochloride is promising for research of autoimmune diseases .
    Amiselimod hydrochloride
  • HY-16734
    Amiselimod

    MT-1303

    		 LPL Receptor Cardiovascular Disease Inflammation/Immunology
    Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases .
    Amiselimod

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: